Urogen Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tara Bancroft from TD Cowen maintained a Buy rating on the stock and has a $35.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tara Bancroft has given her Buy rating due to a combination of factors that highlight Urogen Pharma’s strategic positioning and potential for growth. The launch of Zusduri, a new treatment for recurrent LG/IR NMIBC patients, is expected to be strong due to its impressive duration of response, which significantly surpasses existing surgical options. This has generated substantial interest among physicians, who are keen to prescribe the treatment despite the absence of an initial patient bolus.
Additionally, Urogen Pharma is employing a targeted approach in its early launch phase, focusing on sites that are open to using the current miscellaneous J code. The company plans to leverage its existing network of sales representatives and prescribers, which covers a significant portion of the treatment volume. This strategic focus, coupled with the anticipated reduction in claims processing time once a permanent J code is established, supports the company’s growth prospects and underpins Bancroft’s Buy rating.
Bancroft covers the Healthcare sector, focusing on stocks such as Urogen Pharma, Merus, and Lantheus. According to TipRanks, Bancroft has an average return of -0.7% and a 38.78% success rate on recommended stocks.
In another report released yesterday, Scotiabank also maintained a Buy rating on the stock with a $47.00 price target.